Enfermedad de Parkinson

Por el personal de Mayo Clinic
24 de septiembre de 2026

Investigación

Los médicos de Mayo Clinic capacitados en afecciones del sistema nervioso (neurólogos) y en otras especialidades realizan extensas investigaciones en genética, las causas, nuevas pruebas de diagnóstico y tratamientos para la enfermedad de Parkinson y otros trastornos del movimiento. Por ejemplo, los investigadores de Mayo descubrieron que el análisis de la saliva de una persona puede ser útil para confirmar el diagnóstico de la enfermedad de Parkinson, y esto se puede utilizar como instrumento para que los investigadores comprendan cómo se desarrolla dicha enfermedad. Mediante estudios epidemiológicos, los investigadores de Mayo Clinic también identificaron muchos genes relacionados con la enfermedad de Parkinson, así como muchos factores de riesgo para la enfermedad.

Los investigadores estudian las causas y los tratamientos posibles para la enfermedad de Parkinson. Los médicos también investigan la estimulación cerebral profunda para tratar la enfermedad de Parkinson y otros trastornos del movimiento. Tal vez tenga la oportunidad de participar en estudios de investigación o ensayos clínicos.

Lee más acerca de las investigaciones en los siguientes temas:

Publicaciones

Consulte en PubMed una lista de publicaciones sobre la enfermedad de Parkinson escritas por los médicos de Mayo Clinic. PubMed es un servicio de la National Library of Medicine (Biblioteca Nacional de Medicina).

  1. Parkinson's disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease#. Accessed April 3, 2024.
  2. Kellerman RD. Parkinson's disease. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed April 3, 2024.
  3. Parkinson's disease: Hope through research. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research. Accessed April 3, 2024.
  4. Loscalzo J, et al., eds. Parkinson's disease. In: Harrison's Principles of Internal Medicine. 21st ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed April 4, 2024.
  5. Stoker TB, et al. Parkinson's disease: Pathogenesis and clinical aspects. htps://pubmed.ncbi.nlm.nih.gov/30702835/. Accessed April 4, 2024.
  6. Ferri FF. Parkinson disease. In: Ferri's Clinical Advisor 2022. Elsevier; 2022. https://www.clinicalkey.com. Accessed April 4, 2024.
  7. Jankovic J, et al. Epidemiology, pathogenesis, and genetics of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 4, 2024.
  8. Berg D, et al. Alpha-synuclein seed amplification and its uses in Parkinson's disease. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00124-2.
  9. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
  10. Post B, et al. Young onset Parkinson's disease: A modern and tailored approach. Journal of Parkinson's Disease. 2020; doi:10.3233/JPD-202135.
  11. Ask Mayo Expert. Parkinson disease. Mayo Clinic; 2023.
  12. Caproni S, et al. Diagnosis and differential diagnosis of Parkinson disease. Clinics in Geriatric Medicine. 2020; 10.1016/j.cger.2019.09.014.
  13. Chou KL. Diagnosis and differential diagnosis of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
  14. Medical review (expert opinion). Mayo Clinic. May 16, 2023.
  15. Spindler MA, et al. Initial pharmacologic treatment of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
  16. Hauser RA, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism and Related Disorders. 2019; doi:10.1016/j.parkreldis.2019.03.026.
  17. Mishima T, et al. Personalized medicine in Parkinson's disease: New options for advanced treatments. Journal of Personalized Medicine. 2021; doi:10.3390/jpm11070650.
  18. Jenner P, et al. Istradefylline — A first adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Review of Neurotherapeutics. 2021; doi:10.1080/14737175.2021.1880896.
  19. Isaacson SH, et al. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson's disease psychosis. Journal of Parkinson's Disease. 2020; doi:10.3233/JPD-202047.
  20. Al-Shorafat DM, et al. β-blocker-induced tremor. Movement Disorders Clinical Practice. 2021; doi:10.1002/mdc3.13176.
  21. Taghizadeh M, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International. 2017; doi:10.1016/j.neuint.2017.03.014.
  22. Parkinson's disease: Fitness counts. Parkinson's Foundation. http://www.parkinson.org/pd-library/books/fitness-counts. Accessed April 9, 2024.Green tea. Natural Medicines. https://naturalmedicines.therapeuticresearch.com. Accessed April 9, 2024.
  23. Relaxation techniques for health. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/stress/relaxation.htm. Accessed April 9, 2024.
  24. Haahr A, et al. 'Striving for normality' when coping with Parkinson's disease in everyday life. A metasynthesis. International Journal of Nursing Studies. 2021; doi:10.1016/j.ijnurstu.2021.103923.
  25. Mehanna R, et al. Age cutoff for early-onset Parkinson's disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early-Onset Parkinson's Disease. Movement Disorders Clinical Practice. 2022; doi:10.1002/mdc3.13523.
  26. Nimmagadda R, Allscripts EPSi. Mayo Clinic. May 13, 2024.
  27. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
  28. McKnight S, et al. Toxin-induced Parkinsonism. Neurologic Clinics. 2020; doi:10.1016/j.ncl.2020.08.003.